T-MAXIMUM的现成CAR-T疗法 用于治疗经常性血浆瘤 使FDA在第二阶段试验中领先 T-MAXIMUM's off-the-shelf CAR-T therapy for recurrent glioblastoma gets FDA go-ahead for Phase II trial.

TMAXIMUM制药公司已获得林业发展局批准,将其现成的CAR-T治疗MT027转而进行第二阶段试验,以治疗脑癌这一致命性脑癌复发性血浆瘤。 T-MAXIMUM Pharmaceutical has received FDA approval to move its off-the-shelf CAR-T therapy MT027 into a Phase II trial for recurrent glioblastoma, a deadly brain cancer. 这种治疗是针对肿瘤细胞的B7-H3蛋白质设计的,采用非病毒基因编辑方法,由健康的捐赠者提供,从而能够更快、可扩展的治疗。 The therapy, engineered to target the B7-H3 protein on tumor cells, uses a non-viral gene-editing method and is derived from healthy donors, enabling faster, scalable treatment. 这一进展表明,在将CAR-T技术应用于固态肿瘤、克服诸如血脑屏障等挑战方面取得了进展。 This advancement represents progress in applying CAR-T technology to solid tumors, overcoming challenges like the blood-brain barrier. 美国食品和药物管理局的批准支持T- MAXIMUM在开发治疗大脑转移和其他难以治疗的癌症方面的更广泛努力. The FDA clearance supports T-MAXIMUM’s broader efforts to develop treatments for brain metastases and other hard-to-treat cancers.